Fatal COVID-19 soon after 2nd dose of Pfizer vaccine in an 88-year-old male

An 88-year-old male patient was brought to the emergency department on July 25, 2021, with complaints of shortness of breath, headache, cough, and generalized body weakness. He was screened for SARS-CoV-2, and he tested negative on the rapid antigen test. A subsequent nasopharyngeal swab for the reverse transcription-polymerase chain reaction (RTPCR) test for SARS-CoV-2, however, yielded positive results. He presented with blood pressure (BP) of 136/62 millimeters of mercury (mmHg), a pulse of 113 per minute, oxygen saturation of 52% at room air, a body temperature of 37.3°C, and blood sugar at 6.2 mmol/lite. An examination of the respiratory system revealed coarse crackles with decreased air entry in both lung fields and all other systems were within normal limits. His medical history included diagnosis with benign prostatic hyperplasia (BPH) after a prostate biopsy in 2015. He received the first dose of the Pfizer-BioNTech vaccine on June 8, 2021, and the second dose on July 20, 2021. After admission, Oxygen saturation improved from 52% on room air to 90% on a face mask with oxygen at 10 liters per minute flow. The following day, his blood investigation showed hemoglobin at 11.8 mmol/dl, a white cell count of 7.59 × 109 /l, platelets at 204 × 109 /l, C-reactive protein (CRP) at 214 mg/l, urea at 12.7 mmol/l, creatinine at 113 µmol/l, and eGFR (CKD-EPI formula) at 51 ml/min/1.73m2 . A chest x-ray revealed diffuse bilateral patchy infiltration. He was transferred to the COVID-19 ward and started with dexamethasone 6mg, low molecular weight heparin 40mg, and azithromycin 500 mg. He moved from face mask to high-flow nasal cannula (HFNC) oxygen therapy because he was unable to maintain the target (SpO2 ≥90%) oxygen saturation. He continuously deteriorated despite optimum treatment and died on July 27, 2021. 

READ MORE


REFERENCE

Vaccine Breakthrough Infections of SARS-Cov-2: A Case Report

Ramprakash Kaswa. Vaccine Breakthrough Infections of SARS-Cov2: A Case Report. Ethiop J Health Sci. 2021;32 (1):201. 

doi:http://dx.doi.org/10.4314/ejhs.v32i1. 20 

Contact: Ramprakash Kaswa. Department of Family Medicine and Rural Health, Walter Sisulu University, South Africa *Email: rp.kaswa@gmail.com

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more